AlaskOmega (Omega-3 Fish Oil Concentrate)

AlaskOmega is a concentrated omega-3 fish oil ingredient standardized to deliver at least 650 mg of EPA and DHA per gram, sourced from Alaskan pollock. These long-chain polyunsaturated fatty acids reduce triglycerides, modulate inflammatory signaling, and support cardiovascular function through well-characterized lipid metabolism pathways.

Origin & History

AlaskOmega is a branded omega-3 fish oil concentrate derived from wild-caught Alaska Pollock (Gadus chalcogrammus) from the Bering Sea. The oil is extracted by heating fish remains after roe and fillet removal, then purified and concentrated via molecular distillation, ethyl esterification, and multi-step filtration to achieve up to 85% total omega-3 concentration.

Historical & Cultural Context

No information on historical or traditional medicine use is provided in the research. AlaskOmega is described as a modern branded concentrate from wild Alaska Pollock with no documented ties to traditional systems.

Health Benefits

• No AlaskOmega-specific clinical trials are documented in the research provided
• The manufacturer references over 40,000 studies on EPA and DHA generally, but these are not specific to AlaskOmega
• The product provides concentrated EPA and DHA (≥650 mg/g total) in forms used in clinical research
• Manufacturing process removes contaminants including PCBs, dioxins, and heavy metals
• Low oxidation levels (TOTOX ≤5) maintained through stabilization with mixed tocopherols

How It Works

EPA and DHA are incorporated into phospholipid membranes where they compete with arachidonic acid for cyclooxygenase and lipoxygenase enzymes, reducing synthesis of pro-inflammatory eicosanoids such as thromboxane A2 and leukotriene B4. EPA acts as a substrate for the production of specialized pro-resolving mediators including resolvins and protectins, which actively resolve inflammatory cascades. DHA activates PPARγ nuclear receptors and suppresses NF-κB signaling, contributing to reduced triglyceride synthesis in hepatocytes and improved endothelial nitric oxide bioavailability.

Scientific Research

No specific human clinical trials, RCTs, or meta-analyses on AlaskOmega itself are provided in the research dossier. The manufacturer references general EPA and DHA research but does not cite AlaskOmega-specific trials or provide PMIDs.

Clinical Summary

No clinical trials have been conducted specifically on AlaskOmega as a branded ingredient; its efficacy is inferred from the broader body of EPA and DHA research, which the manufacturer cites as exceeding 40,000 published studies. Landmark trials such as REDUCE-IT (n=8,179) demonstrated that high-dose EPA (4 g/day icosapentaenoic acid ethyl ester) reduced major cardiovascular events by 25% in high-risk patients, while STRENGTH (n=13,078) using a DHA-containing formulation showed no significant benefit, highlighting that outcomes may depend on specific formulation and EPA-to-DHA ratio. Meta-analyses of general omega-3 supplementation consistently show reductions in serum triglycerides of 15–30% at doses of 2–4 g EPA+DHA per day. Because AlaskOmega delivers its EPA and DHA in concentrated triglyceride or re-esterified triglyceride form—formats used in clinical research—bioavailability is considered favorable, but direct comparative data for this specific ingredient remain unpublished.

Nutritional Profile

AlaskOmega is a highly concentrated omega-3 fish oil delivering ≥650 mg/g total EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) combined, sourced from wild Alaskan pollock. Typical concentration yields approximately 360–400 mg/g EPA and 240–280 mg/g DHA, though exact EPA:DHA ratio varies by product specification. The oil is delivered primarily in triglyceride (TG) form, which research suggests offers superior bioavailability compared to ethyl ester (EE) forms — studies indicate triglyceride-form omega-3s are absorbed approximately 50% more efficiently than ethyl esters when taken with food. Caloric contribution is approximately 9 kcal per gram of oil (fat-based). Contains negligible protein, carbohydrates, and fiber. Minor fat-soluble components may include naturally occurring vitamin E (tocopherols) added as an antioxidant to stabilize the oil and prevent oxidation, typically at low preservative doses (1–10 mg/g range). The purification process (molecular distillation or equivalent) removes environmental contaminants including PCBs, dioxins, furans, and heavy metals (mercury, lead, cadmium, arsenic) to below detectable or regulatory limits. Low oxidation status is maintained with TOTOX values controlled during manufacturing, preserving oil integrity and reducing pro-inflammatory oxidized lipid byproducts. No significant micronutrient content (vitamins A, D, K or minerals) is documented at therapeutic concentrations in this concentrate form.

Preparation & Dosage

No clinically studied dosage ranges for AlaskOmega are detailed in the research. Products provide ≥650 mg/g total EPA+DHA with concentrations up to 85% total omega-3s in ethyl ester or re-esterified triglyceride forms. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin E, CoQ10, Astaxanthin, Vitamin D3, Magnesium

Safety & Interactions

AlaskOmega-derived EPA and DHA are generally recognized as safe at doses up to 3 g/day per FDA guidelines, with higher doses used under medical supervision. The most common side effects are gastrointestinal, including fishy aftertaste, nausea, and loose stools, which can be minimized by taking capsules with meals. At doses above 3 g/day, EPA and DHA exhibit mild antiplatelet activity and may potentiate the effects of anticoagulants such as warfarin and antiplatelet drugs like clopidogrel, warranting INR monitoring. Omega-3 fish oil supplementation is considered safe during pregnancy and lactation to support fetal neurodevelopment, though individuals with fish or shellfish allergies should consult a physician before use.